<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140461</url>
  </required_header>
  <id_info>
    <org_study_id>AMBDOSE</org_study_id>
    <nct_id>NCT04140461</nct_id>
  </id_info>
  <brief_title>AmB Dose for Cryptococcal Meningitis</brief_title>
  <official_title>Antifungal Treatment of Cryptococcal Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cryptococcal meningitis (CM) is one of the leading opportunistic infections and one of the
      most common causes of death in AIDS patients.

      Amphotericin B (AmB) is the corner stone in CM treatment. The effect of AmB was
      dose-dependent. Recent retrospective study indicated that longer duration rather than higher
      dose of AmB is necessary to reduce the mortality of CM. We aimed to explore the efficacy and
      safety of small dose but longer duration of AmB for the treatment of HIV-associated CM.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects died at weeks 48</measure>
    <time_frame>48 weeks after randomization</time_frame>
    <description>Mortality in intent to treat population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with CSF culture positive for Cryptococcus at weeks 2</measure>
    <time_frame>2 weeks after randomization</time_frame>
    <description>Antifungal Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with disability at weeks 48</measure>
    <time_frame>48 weeks after randomization</time_frame>
    <description>Disability rate in intent to treat population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>All the adverse events occurred after randomization</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B</intervention_name>
    <description>The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Trial</arm_group_label>
    <other_name>Antiretroviral therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucytosine</intervention_name>
    <description>The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV infection

          -  Naive to antiretroviral therapy

          -  Cryptococcal antigen, smear or culture positive in cerebrospinal fluid

          -  Agree to participate the study

        Exclusion Criteria:

          -  Having receiving antifungal treatment for â‰¥3 days

          -  ALT or AST &gt; 5* upper limit of detection (ULD), or neutrophil&lt; 0.5*10E9 cells/L, or
             hemoglobin &lt; 90g/L or platelet &lt;50*10E9/L or serum creatinine &gt; ULD

          -  Pregnancy or breastfeeding

          -  Concomitant medications that are contraindicated with any research drug

          -  Any other contraindications for using amphotericin B or 5FC

          -  Inability to follow-up as accessed by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Chen, M.D</last_name>
    <phone>+86-21-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>qtchenjun@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Jun Chen</investigator_full_name>
    <investigator_title>Assistant of the department</investigator_title>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>Cryptococcal Meningitis</keyword>
  <keyword>Amphotericin B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

